Oral aprepitant
Products billed under this code include Aprepitant, Emend.
Payment limit per 5 MG, by effective quarter, 1Q21 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.Products billed under this code include Aprepitant, Emend.
Payment limit per 5 MG, by effective quarter, 1Q21 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.From the 4Q26 NDC–HCPCS crosswalk. “Limit / pkg” is the 4Q26 payment limit times the billing units in one package.
| Product | Labeler | NDC | Units / pkg | Limit / pkg |
|---|---|---|---|---|
| Aprepitant | Sandoz Inc. | 00781-2321-06 | 8 | $20.088 |
| Aprepitant | Sandoz Inc. | 00781-2321-51 | 40 | $100.44 |
| Aprepitant | Sandoz Inc. | 00781-2322-46 | 32 | $80.352 |
| Aprepitant | Sandoz Inc. | 00781-2322-68 | 96 | $241.056 |
| Aprepitant | Sandoz Inc. | 00781-2323-68 | 150 | $376.65 |
| Aprepitant | Sandoz Inc. | 00781-4063-36 | 57 | $143.127 |
| Aprepitant | Torrent Pharmaceuticals Limited | 13668-0591-81 | 8 | $20.088 |
| Aprepitant | Torrent Pharmaceuticals Limited | 13668-0591-82 | 40 | $100.44 |
| Aprepitant | Torrent Pharmaceuticals Limited | 13668-0592-84 | 32 | $80.352 |
| Aprepitant | Torrent Pharmaceuticals Limited | 13668-0592-86 | 96 | $241.056 |
| Product | Labeler | NDC | Units / pkg | Limit / pkg |
|---|---|---|---|---|
| Aprepitant | Torrent Pharmaceuticals Limited | 13668-0593-86 | 150 | $376.65 |
| Aprepitant | Torrent Pharmaceuticals Limited | 13668-0594-87 | 57 | $143.127 |
| Aprepitant | BluePoint Laboratories | 68001-0666-01 | 8 | $20.088 |
| Aprepitant | BluePoint Laboratories | 68001-0666-17 | 40 | $100.44 |
| Aprepitant | BluePoint Laboratories | 68001-0667-01 | 32 | $80.352 |
| Aprepitant | BluePoint Laboratories | 68001-0667-19 | 96 | $241.056 |
| Aprepitant | BluePoint Laboratories | 68001-0668-19 | 150 | $376.65 |
| Aprepitant | BluePoint Laboratories | 68001-0669-15 | 57 | $143.127 |
| Aprepitant | Glenmark Pharmaceuticals Inc., USA | 68462-0112-33 | 57 | $143.127 |
| Aprepitant | Glenmark Pharmaceuticals Inc., USA | 68462-0583-40 | 8 | $20.088 |
| Aprepitant | Glenmark Pharmaceuticals Inc., USA | 68462-0583-85 | 40 | $100.44 |
| Aprepitant | Glenmark Pharmaceuticals Inc., USA | 68462-0584-58 | 32 | $80.352 |
| Aprepitant | Glenmark Pharmaceuticals Inc., USA | 68462-0584-76 | 96 | $241.056 |
| Aprepitant | Glenmark Pharmaceuticals Inc., USA | 68462-0585-76 | 150 | $376.65 |
| Emend | Merck Sharp & Dohme LLC | 00006-0461-02 | 32 | $80.352 |
| Emend | Merck Sharp & Dohme LLC | 00006-3066-03 | 25 | $62.775 |
| Emend | Merck Sharp & Dohme LLC | 00006-3862-03 | 57 | $143.127 |
| Quarter | Payment limit | Change | Billing unit | Description | Source file |
|---|---|---|---|---|---|
| 4Q26 | $2.511 | −$0.558 | 5 MG | Oral aprepitant | v1, posted September 17, 2026 |
| 3Q26 | $3.069 | +$0.68 | 5 MG | Oral aprepitant | v1, posted September 15, 2026 |
| 2Q26 | $2.389 | −$0.381 | 5 MG | Oral aprepitant | v1, posted September 15, 2026 |
| 1Q26 | $2.77 | +$0.045 | 5 MG | Oral aprepitant | v1, posted September 15, 2026 |
| 4Q25 | $2.725 | +$0.007 | 5 MG | Oral aprepitant | v1, posted September 8, 2026 |
| 3Q25 | $2.718 | −$0.324 | 5 MG | Oral aprepitant | v1, posted March 10, 2026 |
| 2Q25 | $3.042 | +$0.185 | 5 MG | Oral aprepitant | v1, posted March 10, 2026 |
| 1Q25 | $2.857 | −$0.416 | 5 MG | Oral aprepitant | v1, posted December 19, 2025 |
| 4Q24 | $3.273 | −$0.127 | 5 MG | Oral aprepitant | v1, posted June 11, 2025 |
| 3Q24 | $3.40 | −$0.097 | 5 MG | Oral aprepitant | v1, posted June 11, 2025 |
| 2Q24 | $3.497 | −$0.728 | 5 MG | Oral aprepitant | v1, posted March 11, 2025 |
| 1Q24 | $4.225 | +$0.767 | 5 MG | Oral aprepitant | v1, posted December 19, 2024 |
| 4Q23 | $3.458 | +$0.339 | 5 MG | Oral aprepitant | v1, posted October 10, 2024 |
| 3Q23 | $3.119 | +$0.131 | 5 MG | Oral aprepitant | v1, posted June 5, 2024 |
| 2Q23 | $2.988 | −$0.248 | 5 MG | Oral aprepitant | v1, posted February 23, 2024 |
| 1Q23 | $3.236 | −$0.30 | 5 MG | Oral aprepitant | v1, posted December 6, 2023 |
| 4Q22 | $3.536 | −$0.165 | 5 MG | Oral aprepitant | v1, posted June 22, 2023 |
| 3Q22 | $3.701 | +$0.054 | 5 MG | Oral aprepitant | v1, posted June 9, 2023 |
| 2Q22 | $3.647 | −$0.544 | 5 MG | Oral aprepitant | v1, posted December 14, 2022 |
| 1Q22 | $4.191 | −$0.382 | 5 MG | Oral aprepitant | v1, posted June 8, 2022 |
| 4Q21 | $4.573 | +$0.379 | 5 MG | Oral aprepitant | v1, posted June 2, 2022 |
| 3Q21 | $4.194 | −$0.958 | 5 MG | Oral aprepitant | v1, posted June 2, 2022 |
| 2Q21 | $5.152 | +$0.856 | 5 MG | Oral aprepitant | v1, posted March 1, 2022 |
| 1Q21 | $4.296 | – | 5 MG | Oral aprepitant | v1, posted December 10, 2021 |
“Change” is the difference from the previous quarter, shown only when both quarters have a payment limit and the billing unit is the same. “vs. last quarter” and “vs. a year ago” follow the same rule.